Amgen and UCB push forward with bone-building antibody

Date April 04, 2012

Promising mid-stage results for what could be the first bone-building antibody to treat osteoporosis have encouraged two companies that could use a little help from their pipelines to initiate a phase III trial. Amgen the world’s biggest biotech and UCB the Belgian specialty pharma company today announced plans to test AMG 785 (CDP7851) in 5,000 women in a trial that should report in 2015, and show whether the therapy can reduce the incidence of fractures.

Introducing an expensive biological into what will be a very genercised market – even Eli Lilly’s bone-building incumbent Forteo will be nearing the end of its market exclusivity by the time the Amgen/UCB antibody can reach prescribing physicians – will be a big ask. Still, Forteo, itself a biological, has been able to carve out blockbuster sales even going up against off-patent drugs by targeting high-risk patients and those intolerant to bisphosphonates, suggesting there is still a place for new treatments.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd